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ABSTRACT
Background: Disruptive behavior disorders (DBDs), excluding attention deficit/hyperactivity
disorder (ADHD), are characterized by a repetitive pattern of antisocial, aggressive, and defi-
ant behavior involving major violations of age-appropriate norms, resulting in significant
functional impairment. Risperidone is licensed for the treatment of DBDs in children, ado-
lescents, and adults in several countries. The aim of this study was to determine the effect of
risperidone in a clinical setting on the symptom items of the Nisonger Child Behavior Rating
Form (N-CBRF), used for the assessment of DBD patients.
Method: Data from two 6-week, randomized, double-blind, placebo-controlled trials of
risperidone oral solution (0.02–0.06 mg/kg/day) in children with DBDs and subaverage IQ
(mild, moderate mental retardation and borderline IQ) were pooled for analysis.
Results: Risperidone produced improvement in both the Social Competence and the Prob-
lem Behavior N-CBRF subscales. Risperidone reduced symptoms in the Problem Behavior
subscales (e.g., Conduct Problem, Insecure/Anxious) but also improved positive behaviors on
the Social Competence subscales. Unlike most problem-behavior items, certain items reflecting
“Affective insecurity” (e.g., shy, timid; clings to adults; crying, tearful episodes) failed to im-
prove. This was also true of social disinterest and certain rituals. No items showed any wors-
ening of symptoms with active medication.
Conclusion: Whereas most categories of problem behavior improved with risperidone,
items reflecting “affective insecurity” and some infrequently endorsed items were unaffected
in these children with DBDs and subaverage IQ. These data may provide a more refined knowl-
edge of risperidone’s therapeutic effects in such children.
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INTRODUCTION
CONDUCT DISORDER, oppositional defiant dis-order, and disruptive behavior disorder—
not otherwise specified (NOS) (collectively
referred to in this paper as disruptive behavior
disorders (DBDs)) are among the most wide-
spread forms of psychopathology in children
and adolescents (Steiner 1997). These disorders
affect approximately 6% of children and adoles-
cents. It is widely accepted that behavior prob-
lems occur more frequently in children with
mental retardation than in the general popula-
tion (Einfeld and Aman 1995; Buitelaar 2002).
DBDs are most common in young boys and
those with low intellectual functioning (IQ
under 84), with prevalence rates as high as
64% in children with severe mental retardation
(Bauermeister et al. 1994; Gillberg et al. 1986).
DBDs are characterized by repetitive patterns
of antisocial, aggressive, and defiant behaviors
that violate age-appropriate expectations or
norms, resulting in significant impairment in
functioning. The defining symptoms of DBDs
specified in the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition (DSM-IV)
are very similar to those of conduct disorder
incorporated in International Classification of
Diseases (ICD-10) (American Psychiatric Asso-
ciation 2000; World Health Organization 1992).
Overt aggression is the most common present-
ing symptom for child psychiatric patients with
DBDs (Connor and Steingard 1996).
Ideally, management of DBDs is holistic; treat-
ment should involve behavioral therapy or psy-
chotherapy and parental counseling, and it is
often complimented by pharmacotherapy for
symptom control (Kazdin 1997). As can be seen
by the wealth of literature in this area, off-label
use of medications is common, including con-
ventional antipsychotics, psychostimulants,
mood stabilizers, antidepressants, and presy-
naptic noradrenergic agonists.
Risperidone is a second-generation atypical
antipsychotic medication, and is licensed in sev-
eral countries for treating DBDs in children, ado-
lescents, and adults. Results from two 6-week,
double-blind, randomized, placebo-controlled
trials and three 1-year, open-label trials have
shown risperidone (0.02–0.06 mg/kg/day) to
be a well-tolerated and efficacious treatment
for DBDs in children with IQs ranging from
borderline intellectual functioning to moderate
impairment (Aman et al. 2002; Snyder et al.
2002; Turgay et al. 2002; Findling et al. 2004).
In all of these studies, the Nisonger Child
Behavior Rating Form (N-CBRF) (Aman et al.
1996) was used, along with other behavior mea-
surement tools, to determine the efficacy of
risperidone in treating disruptive behavioral
symptoms. The N-CBRF is an informant behav-
ior rating scale constructed for assessing psy-
chopathology and maladaptive behaviors in
children and adolescents with developmental
disabilities and/or borderline IQs (Aman et al.
1996). The N-CBRF comprises two sections:
Social Competence and Problem Behavior, with
subscales within each.
The aim of this study was to determine which
symptoms, as represented by items on the N-
CBRF, responded to treatment with risperidone.
METHODS
Study design
This was a pooled analysis of N-CBRF item
ratings from two 6-week, randomized, double-
blind, placebo-controlled trials in which the
safety and efficacy of oral risperidone solution
(0.02–0.06 mg/kg/day) were assessed in chil-
dren with DBDs. Full particulars of trial design,
as well as inclusion/exclusion, can be found in
the cited publications (Aman et al. 2002; Sny-
der et al. 2002; designated here as RIS-USA-93
and RIS-CAN-19, respectively).
Behavioral outcome variables
The studies used the parent (as opposed to
the teacher) version of the N-CBRF, which has
the following subscales: Part A (Social Com-
petence): 1. Compliant/Calm (6 items), 2.
Adaptive/Social (4 items); Part B (Problem Be-
havior): 1. Conduct problem (16 items), 2. Inse-
cure/Anxious (15 items), 3. Hyperactive (9
items), 4. Self-Injury/Stereotypic (7 items), 5.
Self-Isolated/Ritualistic (8 items), and 6. Overly
Sensitive (5 items). The Social Competence items
are scored on a 4-point Likert scale ranging from
0 (not true) through 3 (completely or always
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true). Each Problem Behavior item is also scored
on a 4-point scale, ranging from 0 (behavior
did not occur or was not a problem) through 3
(behavior occurred a lot or was a severe prob-
lem). Although the Conduct Problem subscale
was the primary outcome measure for the orig-
inal reports, no data from this subscale are pre-
sented here, as the emphasis of this analysis is
on other behaviors affected by risperidone.
Copies of the instrument are available free of
charge in PDF format from the senior author
(MGA) or from the Appendix. The analysis de-
scribed in this paper focuses on an item analy-
sis of the N-CBRF (Snyder et al. 2002; Aman et
al. 2002).
Subjects
The studies involved children 5–12 years of
age inclusive, with clinician-assessed DSM-IV
diagnosis of conduct disorder, oppositional
defiant disorder, or disruptive behavior disor-
der—not otherwise specified (NOS) who had a
DSM-IV Axis II diagnosis of borderline intel-
lectual functioning or mild-to-moderate men-
tal retardation (IQ in the range of 36–84) and a
parent-assessed rating of at least 24 in the Con-
duct Problem subscale of the N-CBRF. Any per-
vasive developmental disorder, schizophrenia
or other psychotic disorders, head injury as a
cause of the mental impairment, or seizure dis-
order requiring medication were all exclusion-
ary criteria. Previous exposure to risperidone,
history of tardive dyskinesia or neuroleptic ma-
lignant syndrome, presence of human immu-
nodeficiency virus, and serious or progressive
illness were also exclusion criteria. Subjects were
required to be free of other medicines except
for previously established regimens of psycho-
stimulants (for ADHD), and chloral hydrate,
antihistamines, or melatonin (for sleep). Such
prior medication had to be in place at constant
dosage for at least 30 days before the trial started,
and dosage had to be held constant during the
trial. Thirty-three percent of the placebo group
and 42% of the risperidone-treated subjects re-
ceived constant doses of stimulants during the
trial. All patients included in the intent-to-treat
studies were included in the pooled analysis of
the N-CBRF items. For a summary of the char-
acteristics and diagnostic classifications of the
subjects, see Table 1.
Subjects were recruited at a multitude of sites,
and recruitment procedures differed across sites.
In some cases, the participants were patients of
the investigators, whereas in other cases the
participants were recruited from a multitude
of sources, such as special education settings,
psychiatric and pediatric practices, parent news-
letters, and radio advertising. Parents rated
their children on the Child Symptom Inventory
(CSI) (Gadow and Sprafkin, 1994), an informant
rating scale designed to screen for all disorders
common in childhood and adolescence. Physi-
cians and licensed psychologists then made
the diagnoses of conduct disorder, oppositional
defiant disorder, or disruptive behavior disor-
der NOS and, if present, ADHD.
Data analysis
The two randomized, double-blind, placebo-
controlled trials were combined for an analysis
of the N-CBRF items. An analysis of covariance
(ANCOVA) was performed on the change score
(baseline to endpoint) to assess the differences
between risperidone and placebo. The factors
used were trial (RIS-CAN-19 or RIS-USA-93)
and treatment, with baseline scores entered as
a covariate. The Interactions between baseline
scores and treatment were not assessed. Degrees
of freedom throughout were 1 and 219 for the
drug comparison. Although the 4-point Likert
scale used for the individual items might sug-
gest choice of a nonparametric statistic, we
opted for the ANCOVA, because the ANCOVA
model enabled us to control for subjects’ base-
line scores, study, and site differences. Com-
puter-simulation studies have shown that the
use of the ANCOVA model is appropriate and
renders accurate alpha levels when applied to
clinical ordinal data such as these, provided
that the sample size is large (true here) (Sulli-
van and D’Augustino, Sr. 2003). Because of the
large number of comparisons conducted, we
set the alpha probability level at 0.01. As this
might permit some spurious items to emerge
as “significant,” items identified between 0.01
and 0.001 might best be viewed as reflecting
statistical “trends.”
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RESULTS
Subjects
In total, 223 patients were included in the
pooled-analysis sample. With the exception of
ethnicity, patients in both trials (Aman et al.
2002; Snyder et al. 2002) were comparable in
terms of baseline characteristics and psychiatric
history (see Table 1).
N-CBRF item analysis
Previously published studies (Aman et al.
2002; Snyder et al. 2002) used the Conduct
Problem subscale as the primary outcome vari-
able and showed that it was, statistically, sig-
nificantly improved compared with placebo
(p < 0.001). Therefore, this paper will focus on
the other subscale items (exclusive of Conduct
Problem), namely, the Social Competence sub-
scales (Compliant/Calm and Adaptive/Social),
and the remaining Problem Behavior subscales
(Insecure/Anxious, Hyperactive, Self-Injury/
Stereotypic, Self-Isolated/Ritualistic, and Overly
Sensitive).
Social Competence section. The Social Compe-
tence section subscale items that were most
significantly improved (p < 0.001) with risperi-
done were: 1. “accepted redirection,” 4. “initi-
ated positive interactions,” 10. “been patient,
able to delay,” 2. “expressed ideas clearly,” 5.
“participated in group activities,” and 7. “shared
with or helped others.” At the p < 0.01 level,
the significantly improved items were: 3. “fol-
lowed rules,” and 8. “stayed on-task” (see Table
2). Effect sizes (presented in Table 2) for signif-
icant items ranged from 0.29 to 0.48.
Problem Behavior section. For the Insecure/
Anxious subscale, the majority of items were
markedly improved with risperidone at end-
point, compared to placebo (see Table 3). The
items most significantly improved (p < 0.001)
with risperidone were: 31. “nervous or tense,”
41. “says no one likes him or her,” 42. “secre-
tive, keeps things to self,” and 55. “talks too
much or too loud.” Items 16. “exaggerates abil-
ities or achievements,” 21. “feels others are
against him or her,” 30. “lying or cheating,” 48.
“steals,” 52. “sulks, is silent and moody,” and
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TABLE 1. BASELINE DEMOGRAPHIC AND PSYCHIATRIC HISTORY CHARACTERISTICS
Baseline characteristics CAN-19 USA-93 Pooled
Number 109 114 223
Age (mean) 8.7 8.3 8.5
Sex (M/F) 82/27 93/21 175/48
(75%/25%) (82%/18%) (79%/21%)
Race
Black 8 (7%) 38 (33%) 46 (21%)
Caucasian 83 (76%) 65 (57%) 148 (66%)
Hispanic — 6 (5%) 6 (3%)
Asian — 1 (1%) 1 (<1%)
Other 18 (17%) 4 (4%) 22 (10%)
Psychiatric history
CD 10 (9%) 20 (18%) 30 (13%)
CD + ADHD 31 (28%) 25 (22%) 56 (25%)
DBD NOS 4 (4%) 2 (2%) 6 (3%)
DBD NOS + ADHD 6 (5%) 6 (5%) 12 (5%)
ODD 12 (11%) 24 (21%) 36 (16%)
ODD + ADHD 47 (43%) 37 (32%) 84 (37%)
Intellectual handicap
Borderline 53 (48%) 57 (50%) 110 (49%)
Mild 42 (38%) 37 (32%) 79 (35%)
Moderate 15 (14%) 20 (18%) 35 (16%)
CD, conduct disorder; ADHD, attention-deficit/hyperactivity disorder; DBD NOS, disruptive behavior disorder—
not otherwise specified; ODD, oppositional defiant disorder.
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60. “too fearful or anxious” were significant at
the p < 0.01 level. Effect sizes ranged from 0.28
(“sulks”) to 0.47 (“talks too much”) (see Table
3). The items for which there was no signifi-
cant difference between risperidone and placebo
at endpoint were: 34. “overly anxious to please
people,” 44. “self-conscious or easily embar-
rassed,” and 65. “worrying.”
On the Hyperactivity subscale, items that
were significantly improved with risperidone
were: 33. “overactive, doesn’t sit still” [F(1219) =
12.07; Effect size (ES), 0.44), 39. “restless, high
energy level” (F = 11.33; ES, 0.42) (p < 0.001),
and 13. “easily distracted” (F = 9.64; ES, 0.38),
19. “fails to finish things he or she starts” (F =
9.83; ES, 0.38), and 46. “short attention span”
(F = 9.02; ES, 0.39)(p < 0.01). On the Self-Injury/
Stereotypic subscale, only 53. “physically harms/
hurts self on purpose” (F = 10.90; ES, 0.21) was
significantly improved (p < 0.01) with risperi-
done. For the Self-Isolated/Ritualistic subscale,
3 of the 8 items were significantly improved
with risperidone compared to placebo at end-
point (see Table 4). These were: items 29. “iso-
lates self from others,” 37. “refuses to talk,”
and 49. “odd repetitive behaviors.” Effect sizes
ranged from 0.22 (item 49) to 0.29 (item 37).
The 3 items for which there was no significant
difference at endpoint between risperidone
and placebo were: 1. “disinterested or unmoti-
vated,” 18. “rituals: head rolling or floor pac-
ing,” and 47. “shy or timid behavior.” On the
Overly Sensitive subscale, the only significantly
improved item was: 14. “easily frustrated” (F =
17.66; ES, 0.52) (p < 0.001). Other items, not as-
signed to a subscale, that were significantly
improved with risperidone were: 51. “sudden
changes in mood” (F = 10.39; ES, 0.43) (p < 0.01)
and 27. “irritable” (F = 13.62; ES, 0.45) (p < 0.001).
DISCUSSION
Social Competence section items
One finding from this analysis was the im-
pact that risperidone had on individual positive
social behaviors, as shown by improvements
in items on the Compliant/Calm and Adap-
tive/Social subscales. Based on results in Table
2, the most dramatic effects on the Compli-
ance/Calm subscale were observed with symp-
toms of rule-governed behavior and parental
guidance. Parents rated their children as better
able to accept guidance, show patience, and
follow rules. The affective items showed less
effect. On the Adaptive/Social subscale, there
was a significant increase in interaction, social-
ization, sharing, and group activities with
risperidone. The improvement in social behav-
iors, and especially rule-governed behaviors,
may lead to better integration in the home,
school, and society. Children who are recep-
tive to parental and teacher guidance may be
better able to study, find suitable employment,
and avoid criminal activity.
Insecure/Anxious subscale items
It is interesting that the items relating to mood
symptoms, such as social anxiety (“overly anx-
ious to please people,” “self-conscious or eas-
ily embarrassed,” “worrying”—see Table 3),
were not very sensitive to medication. As in
the case of greater socialization with medica-
tion, this deserves objective study in its own
right. When more is known about the various
atypical antipsychotic medications, these kinds
of subtle differences in effect may be a basis for
choosing one medicine over another. The lack
of effect on shyness may also indicate informant
discrimination between certain items and the
lack of “halo effect,” at least for certain items.
A “halo effect,” commonly quoted in the litera-
ture, occurs when a rater perceives improve-
ments in all symptoms with medication when,
actually, only a prominent symptom (often,
aggression in the DBDs) has been reduced. As
indicated further below, lack of change could
be seen as “therapeutic” in such children.
Hyperactive subscale items
In the two trials analyzed here, up to 60% of
the children with DBD were diagnosed with
ADHD. The earliest antipsychotics used to treat
ADHD had an effect on physical activity but
not on attention. With risperidone, such a dis-
tinction was not evident, as improvements in
both physical activity symptoms and attention
span were rated as occurring. However, we
cannot assume that perceived improvements
226 AMAN ET AL.
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in attention span are real and, therefore, it would
be helpful to gather independent data on this
(e.g., from vigilance tasks) in future trials.
Thirty-three percent of placebo subjects and
42% of risperidone subjects were taking psy-
chostimulants. However, this should not have
affected our findings, as stimulant therapy had
to be stabilized at least 30 days prior to the
study and held constant throughout.
Self-Injury/Stereotypic subscale items
The characteristic item for stereotypic be-
havior, rocking, was unaffected by medication.
Most self-injury items were moderately affected,
while the only item to reach the 0.01 level of
significance was “self-harm.” However, one of
the authors (MA) noted that such self-harm
often appeared to be incidental and tantrum
associated (i.e., a side effect of throwing one-
self around in rebellion), as compared with vo-
litional repetitive and mechanical self-harm
sometimes seen in such patients.
Self-Isolated/Ritualistic subscale
On the Self-Isolated/Ritualistic subscale (see
Table 4), an improvement in the “refuses to talk”
and “isolates self from others” items suggests
an increased interest or willingness to interact
with others or engage in prosocial behaviors
toward others (consistent with Social Compe-
tence section items). Response of these symp-
toms may also relate to the domain of negative
symptoms. As in the case of prosocial behav-
iors mentioned above, these changes may be
linked to observations in adult schizophrenic
patients on risperidone medication, demonstrat-
ing a beneficial effect on negative symptoms of
schizophrenia. Negative symptoms may be phe-
nomenologically related to social withdrawal
in behavioral and developmental disorders.
As noted earlier, the “shy or timid behavior,”
“disinterested or unmotivated,” and “ritualistic:
Head rolling or floor pacing” items were not
affected by medication. The lack of change
with “shy or timid behavior” is consistent with
the affective items identified under the Inse-
cure/Anxious subscale and adds credibility to
the notion that “affective insecurity” was not
modified in these children. In an odd kind of
way, we might argue that stability on such
items may be fruitful for children with DBDs.
Some degree of anxiousness to please others
may be related to a child’s decision to adhere
to basic rules set out by our society.
The lack of change on the “disinterested or
unmotivated” and “rituals: Head rolling or floor
pacing” items are not easily put in any context.
Disinterest would seem to be related to the
prosocial items that did show change, and the
lack of effect on this item is difficult to explain.
Most of the participants in this analysis had
either borderline IQs or mild mental retarda-
tion. Therefore, the lack of effect on “ritualistic/
head rolling” may be a floor effect, as stereotypic
behavior is often strongly related to severity of
functional handicap. In fact, the modal score
on this item was 0.
Other items
There was no or limited observed effect on
the Overly Sensitive items except the “easily
frustrated” item. One could link the “easily frus-
trated” item as part of the “Conduct” constel-
lation subscale. Most of the remaining items
on this subscale (“clings to adults,” “crying, tear-
ful episodes,” “overly sensitive,” and “feelings
easily hurt”) also appear to reflect our con-
struct of “affective insecurity.” It is very inter-
esting that such items repeatedly emerged as
unaffected by the active drug.
CONCLUSIONS
Beyond any effect on conduct problem symp-
toms, risperidone also appeared to improve as-
pects of social interaction, feelings of self-worth,
and reintegration. The significant improvements
noted in factors measuring rule-governed be-
havior, isolation, socialization, and group-shar-
ing activities may offer hope for additional
changes in these aspects of human interaction.
There was a lack of effect on several mood-
related items reflecting “affective insecurity.”
At this stage, it is not clear if this is an area
uninfluenced by risperidone or if it reflects pe-
culiarities of this analysis. If a more general ef-
fect, it may tell us more about the action of this
medication in children with DBDs. In the same
228 AMAN ET AL.
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way that a degree of anxiety in a job interview
may be regarded as “healthy” (i.e., the person
cares enough about the position to become ner-
vous), some level of “insecurity” may be thera-
peutic in these children.
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PARENT VERSION
Child's Name:                                                                      Child's Date of Birth:              /           /            
                                                             month        day           year     
Rater's Name:                                                                      Date of Rating:              /           /            
                                                             month         day          year     
Relation of Rater to Child: ❏   parent [1] ❏   other [9]:                                                                                  
                                                            (please specify)                                           
THE NISONGER CHILD BEHAVIOR RATING FORM
I. Please describe any special circumstances or mediating factors that may have affected the child's behavior in the
recent past (the last month or two) or prevented you from making complete ratings.
II. POSITIVE SOCIAL.  Please describe the child's behavior as it was at home over the last month.
IN THE LAST MONTH, THIS CHILD HAS:
Not
True
[0]
Somewhat or 
Sometimes
True
[1]
Very or 
Often True
[2]
Completely or
Always True
[3]
  1. Accepted redirection
  2. Expressed ideas clearly
  3. Followed rules
  4. Initiated positive interactions
  5. Participated in group activities
  6. Resisted provocation, was tolerant
  7. Shared with or helped others
  8. Stayed on task
  9. Was cheerful or happy
10. Was patient, able to delay
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
❏
APPENDIX A
Readers are encouraged to duplicate and use this scale in their clinical practice.
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0.... if the behavior did not occur or was not a problem
1.... if the behavior occurred occasionally or was a mild problem
2.... if the behavior occurred quite often or was a moderate problem
3.... if the behavior occurred a lot or was a severe problem
Nisonger CBRF: Parent
III. PROBLEM BEHAVIOR.  For each item that describes the child's behavior as it was over the last month, circle
the:
For each problem that occurred, circle only the score that best describes the behavior. 
PLEASE DO NOT SKIP ANY QUESTIONS.  IF YOU DO NOT KNOW THE ANSWER OR HAVE NOT HAD A CHANCE TO
OBSERVE THE CHILD FOR A GIVEN TIME, CIRCLE THE ZERO.
Readers are encouraged to duplicate and use this scale in their clinical practice.
  1. Apathetic or unmotivated . . . . . . . . . . . . . . . . . . 0
  2. Argues with parents, teachers, or 
other adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
  3. Clings to adults, too dependent . . . . . . . . . . . . 0
  4. Cruelty or meanness to others . . . . . . . . . . . . . . 0
  5. Crying, tearful episodes . . . . . . . . . . . . . . . . . . . 0
  6. Hits or slaps own head, neck, hands,
or other body parts . . . . . . . . . . . . . . . . . . . . . . . 0
  7. Defiant, challenges adult authority . . . . . . . . . . 0
  8. Knowingly destroys property . . . . . . . . . . . . . . 0
  9. Difficulty concentrating . . . . . . . . . . . . . . . . . . . 0
10. Disobedient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
11. Rocks body or head back and forth
repetitively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
12. Doesn't feel guilty after misbehaving . . . . . . . . 0
13. Easily distracted . . . . . . . . . . . . . . . . . . . . . . . . . . 0
14. Easily frustrated . . . . . . . . . . . . . . . . . . . . . . . . . . 0
15. Overly sensitive; feelings easily hurt . . . . . . . . 0
16. Exaggerates abilities or achievements . . . . . . . 0
17. Explosive, easily angered . . . . . . . . . . . . . . . . . . 0
18. Has rituals such as head rolling or 
floor pacing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
19. Fails to finish things he/she starts . . . . . . . . . . 0
20. Feelings easily hurt . . . . . . . . . . . . . . . . . . . . . . . 0
21. Feels others are against him/her . . . . . . . . . . . . 0
22. Harms self by scratching skin or 
pulling hair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
23. Feels worthless or inferior . . . . . . . . . . . . . . . . . 0
24. Fidgets, wiggles, or squirms . . . . . . . . . . . . . . . . 0
25. Shy around others; bashful . . . . . . . . . . . . . . . . 0
26. Gets in physical fights . . . . . . . . . . . . . . . . . . . . . 0
27. Irritable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
28. Repeatedly flaps or waves hands, fingers
or objects (such as pieces of string) . . . . . . . . . 0
29. Isolates self from others . . . . . . . . . . . . . . . . . . . 0
30. Lying or cheating . . . . . . . . . . . . . . . . . . . . . . . . . 0
31. Nervous or tense . . . . . . . . . . . . . . . . . . . . . . . . . 0
32. Gouges self, puts things in ears, nose, 
etc., or eats inedible things . . . . . . . . . . . . . . . . . 0
33. Overactive, doesn't sit still . . . . . . . . . . . . . . . . . 0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
34. Overly anxious to please others . . . . . . . . . . . . 0
35. Overly excited, exuberant . . . . . . . . . . . . . . . . . . 0
36. Physically attacks people . . . . . . . . . . . . . . . . . . 0
37. Refuses to talk . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
38. Repeats the same sound, word, or
phrase over and over . . . . . . . . . . . . . . . . . . . . . 0
39. Restless, high energy level . . . . . . . . . . . . . . . . 0
40. Runs away from adults, teachers, or 
other authority figures . . . . . . . . . . . . . . . . . . . . 0
41. Says no one likes him/her . . . . . . . . . . . . . . . . . . 0
42. Secretive, keeps things to self . . . . . . . . . . . . . . 0
43. Repeatedly bites self hard enough to
leave tooth marks or break skin . . . . . . . . . . . . . 0
44. Self-conscious or easily embarrassed . . . . . . . 0
45. Shifts rapidly from topic to topic
when talking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
46. Short attention span . . . . . . . . . . . . . . . . . . . . . . 0
47. Shy or timid behavior . . . . . . . . . . . . . . . . . . . . . 0
48. Steals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
49. Odd repetitive behaviors (e.g., stares,
grimaces, rigid postures) . . . . . . . . . . . . . . . . . . 0
50. Stubborn, has to do things own way . . . . . . . . 0
51. Sudden changes in mood . . . . . . . . . . . . . . . . . . 0
52. Sulks, is silent and moody . . . . . . . . . . . . . . . . . 0
53. Physically harms or hurts self on
purpose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
54. Talks back to teacher, parents, or 
 
other adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
55. Talks too much or too loud . . . . . . . . . . . . . . . . 0
56. Temper tantrums . . . . . . . . . . . . . . . . . . . . . . . . . 0
57. Threatens people . . . . . . . . . . . . . . . . . . . . . . . . . 0
58. Threatens to harm self . . . . . . . . . . . . . . . . . . . . 0
59. Engages in meaningless, repetitive
body movements . . . . . . . . . . . . . . . . . . . . . . . . . 0
60. Too fearful or anxious . . . . . . . . . . . . . . . . . . . . . 0
61. Underactive, slow . . . . . . . . . . . . . . . . . . . . . . . . 0
62. Unhappy or sad . . . . . . . . . . . . . . . . . . . . . . . . . . 0
63. Violates rules . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
64. Withdrawn, uninvolved with others . . . . . . . . . 0
65. Worrying . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
66. Argues with other children or peers . . . . . . . . . 0
1
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1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
13961C11.pgs  5/3/05  11:51 AM  Page 231
232 AMAN ET AL.
Child's Name:                                                                                                    Child's Date of Birth:              /           /            
                                                            month       day          year    
Rater's Name:                                                                                                            Date of Rating:              /           /            
                                                             month        day          year    
Relation of Rater to Child: ❏ ❏  parent [1]   other [9]:                                                                                                 
     
                                                            (please specify)                                                       
PARENT VERSION: SCORE SHEET
THE NISONGER CHILD BEHAVIOR RATING FORM
INSTRUCTIONS.  Transcribe the ratings from the Nisonger CBRF and write them into the "rating" column next to the
appropriate item number "#". When all ratings have been transcribed, total the columns to obtain the subscale scores.
II. POSITIVE SOCIAL III. PROBLEM BEHAVIOR
Compliant /
Calm
Adaptive
Social
Conduct
Problem
Insecure /
Anxious Hyperactive
Self-Injury / 
Stereotypic
Self-Isolated /
Ritualistic
Overly
Sensitive
# rating # rating # rating # rating # rating # rating # rating # rating
1 2 2 16  9 6 1 3
3 5 4 21 13 11 18 5
4 7 7 23 19 22 25 14
6 8 8 30 24 32 29 15
9 Total 10 31 33 43 37 20
10 12 34 35 53 47 Total
Total 17 41 38 58 49
26 42 39 Total 64
36 44 46 Total
40 45 Total
50 48
54 52
56 55
57 60
63 65
66 Total
Total
Developed by M. G. Aman, M. J. Tassè, J. Rojahn, and D. Hammer: The Nisonger CBRF: A child behavior rating form for children with
developmental disabilities. Res Dev Disabil 17:41–57, 1996.
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